Author:
Lyseng-Williamson Katherine A.,Duggan Sean T.,Keating Gillian M.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine,Biotechnology
Reference22 articles.
1. Duggan ST, Keating GM. Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi’s sarcoma. Drugs. 2011;71(18):2531–58.
2. Caelyx 2 mg/ml concentrate for solution for infusion: summary of product characteristics. London: European Medicines Agency; 2012.
3. Doxil® (doxorubicin HCl liposome injection) for intravenous infusion: US prescribing information. Raritan: Centocor Ortho Biotech Products, LP; 2012.
4. O’Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (Caelyx/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15(3):440–9.
5. Jäger E, Al-Batran S, Saupe S, et al. A randomized phase III study evaluating pegylated liposomal doxorubicin (PLD) versus capecitabine (CAP) as first-line therapy for metastatic breast cancer (MBC): results of the PELICAN study [abstract no. 1022]. J Clin Oncol. 2010;15 Suppl.
Cited by
34 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献